Zemaira Purple Book BLA 125078

BLA number
125078
Proprietary names
Zemaira
Proper names
Alpha-1-Proteinase Inhibitor (Human)
Applicant
CSL Behring LLC
Center
CBER
First observed release
2020-08-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001ZemairaAlpha-1-Proteinase Inhibitor (Human)351(a)1000MGFor InjectionIntravenousSingle-Dose VialRxLicensed2003-07-08
002ZemairaAlpha-1-Proteinase Inhibitor (Human)351(a)4000MGFor InjectionIntravenousSingle-Dose VialRxLicensed2019-04-16
003ZemairaAlpha-1-Proteinase Inhibitor (Human)351(a)5000MGFor InjectionIntravenousSingle-Dose VialRxLicensed2019-04-16

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2021-05-01U001Zemaira351(a)RxCSL Behring LLC
2021-05-01U002Zemaira351(a)RxCSL Behring LLC
2021-05-01U003Zemaira351(a)RxCSL Behring LLC
2020-08-01R001Zemaira351(a)RxCSL Behring LLC
2020-08-01R002Zemaira351(a)RxCSL Behring LLC
2020-08-01R003Zemaira351(a)RxCSL Behring LLC

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2020-08-01001Zemaira351(a)RxLicensed2003-07-08
2020-08-01002Zemaira351(a)RxLicensed2019-04-16
2020-08-01003Zemaira351(a)RxLicensed2019-04-16